← Literature

Afamelanotide for Erythropoietic Protoporphyria.

rct • 2015 • ID: 26132941

High Confidence RCT

Primary source: [Open]

Linked compounds: melanotan-i

Outcomes summary

Randomized trial evaluating afamelanotide (a melanocortin peptide; often discussed under Melanotan I/afamelanotide) for erythropoietic protoporphyria, reporting improved tolerance of light exposure and reduced phototoxicity-related outcomes versus placebo in the studied setting.

Limitations

Rare-disease population; outcomes are condition-specific; device/implant formulation limits generalizability to other contexts.

Notes

Primary source: PMID 26132941.